Pfizer Inc To Acquire Seagen Inc Transcript
Good day, everyone. And welcome to Pfizer's Analyst and Investor Call to review full year 2024 financial guidance. Today's call is being recorded.
At this time, I would like to turn the call over to Francesca DeMartino, Chief Investor Relations Officer and Senior Vice President. Please go ahead, ma'am.
Good morning, and welcome to Pfizer's Call to discuss the Seagen acquisition, changes to our commercial organization and our 2024 financial guidance.
I'm Francesca DeMartino, Chief Investor Relations Officer. On behalf of the Pfizer team, thank you for joining us. This call is being made available via audio webcast at pfizer.com.
Earlier this morning, we released our 2024 financial guidance via press release that is available on our website at pfizer.com. I'm joined today by Dr. Albert Bourla, our Chairman and CEO; and Dave Denton, our CFO.
Albert and Dave have some prepared remarks, and we will then open the call for questions. For the Q&A session, we'll also be
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |